Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by bigslapperon May 30, 2018 6:00pm

246 Views

Post# 28101853

RE:When do you expect a larger movement in stockprice?

No one here has the exact answer you're looking for.
Id sell your weed stock and at least have a position in Antibe.
Mug is right , news will come at any time in any form. This is a stock i havent wanted to be out of since July 2016. Granted, we've seen ups and downs but management hasnt and wont let us down. Everything said in the letter to shareholds has been happening.

Share with us what has "higher probability" then ATE. Id invest in that too !

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale